Special Issue

Topic: Resistance to Systemic Therapies in Renal Cell Carcinoma

A Special Issue of Cancer Drug Resistance

ISSN 2578-532X (Online)

Submission deadline: 28 Feb 2023

Guest Editor(s)

Prof. Guru P. Sonpavde
Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Special Issue Introduction


The treatment of metastatic clear cell renal cell carcinoma (RCC) has evolved significantly over the past two decades with the emergence of vascular endothelial growth factor (VEGF) inhibitors, immune checkpoint inhibitors (ICI) and their combinations, which have largely displaced cytokine therapy. More recently, belzutifan, a HIF-2α inhibitor, has emerged as an active agent and is being evaluated vigorously. The application of these novel agents in the early high-risk ccRCC setting appears promising, with the recent emergence of a role for adjuvant pembrolizumab. Furthermore, the role of MET in driving papillary RCC led to the development of MET inhibitors to improve outcomes. However, despite these advances and improved survival, cure remains elusive for the vast majority of patients with metastatic RCC. Ultimately, cure for most patients will only arrive with better knowledge about the mechanisms of resistance and drivers of tumor growth. Clearly, the development of rational and tolerable combinations of agents may be necessary in most settings. This issue of the Cancer Drug Resistance will take the reader on an exciting journey highlighting emerging information regarding mechanisms of resistance, which may inform us toward developing the next waves of novel treatments.

Submission Deadline

28 Feb 2023

Submission Information

For Author Instructions, please refer to https://www.oaepublish.com/cdr/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=cdr&SpecialIssueId=CDR220525
Submission Deadline: 28 Feb 2023
Contacts: Lori Kang, Assistant Editor, lorikang2018@gmail.com

Published Articles

Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma

Open Access Review DOI: 10.20517/cdr.2023.89 27 Dec 2023
Views: Downloads:
Download PDF

Emerging resistance vs. losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomena

Open Access Review DOI: 10.20517/cdr.2023.47 19 Sep 2023
Views: Downloads:
Download PDF

Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma

Open Access Review DOI: 10.20517/cdr.2023.33 1 Aug 2023
Views: Downloads:
Download PDF

Mechanisms and clinical implications in renal carcinoma resistance: narrative review of immune checkpoint inhibitors

Open Access Review DOI: 10.20517/cdr.2023.02 26 Jun 2023
Views: Downloads:
Download PDF

Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma

Open Access Review DOI: 10.20517/cdr.2023.09 29 May 2023
Views: Downloads:
Download PDF
Cancer Drug Resistance
ISSN 2578-532X (Online)
Follow Us

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/